Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Photodermatol Photoimmunol Photomed ; 36(1): 29-33, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31374130

RESUMO

BACKGROUND: Erythropoietic protoporphyria (EPP) is a semi-dominantly inherited porphyria presenting with photosensitivity during early childhood. Acquired EPP has been reported; however, data regarding this rare disorder are scarce. PURPOSE: To evaluate the characteristics of acquired EPP. METHODS: A comprehensive search of PubMed, Google Scholar, ScienceDirect, and clinicaltrials.gov databases was performed by three reviewers. Studies describing patients with acquired EPP were included. Additionally, we present an index case of a 26-year-old patient who acquired clinically and biochemically typical EPP in association with myelodysplastic syndrome (MDS). RESULTS: We included 20 case reports describing 20 patients. Most (80%) patients were male of mean age 58 ± 13 years. In all patients, acquired EPP was associated with hematological disease, most commonly MDS (85%) followed by myeloproliferative disease (10%). In 86% of cases, hematological disease led to abnormality or somatic mutation in chromosome 18q (the locus of the ferrochelatase gene). The mean erythrocyte protoporphyrin IX concentration was very high (4286 µg/dL). Most (90%) patients presented with photosensitivity, 20% experienced blistering, and 25% presented with hepatic insufficiency, both uncommon in EPP. In 55% of patients, hematological disease was diagnosed after occurrence of cutaneous symptoms. Beta-carotene led to partial control of symptoms in 5 patients and resolution in another patient. Azacitidine treatment of MDS led to resolution of cutaneous symptoms in three patients. CONCLUSION: We present the distinct features of acquired EPP and highlight that any patient presenting with new-onset photosensitivity, irrespective of age should be evaluated for porphyria.


Assuntos
Azacitidina/uso terapêutico , Síndromes Mielodisplásicas , Transtornos de Fotossensibilidade , Protoporfiria Eritropoética , beta Caroteno/uso terapêutico , Adulto , Idoso , Cromossomos Humanos Par 18/genética , Cromossomos Humanos Par 18/metabolismo , Eritrócitos/metabolismo , Feminino , Ferroquelatase/genética , Ferroquelatase/metabolismo , Loci Gênicos , Humanos , Masculino , Pessoa de Meia-Idade , Mutação , Síndromes Mielodisplásicas/tratamento farmacológico , Síndromes Mielodisplásicas/genética , Síndromes Mielodisplásicas/metabolismo , Transtornos de Fotossensibilidade/induzido quimicamente , Transtornos de Fotossensibilidade/tratamento farmacológico , Transtornos de Fotossensibilidade/genética , Transtornos de Fotossensibilidade/metabolismo , Protoporfiria Eritropoética/induzido quimicamente , Protoporfiria Eritropoética/tratamento farmacológico , Protoporfiria Eritropoética/genética , Protoporfiria Eritropoética/metabolismo , Protoporfirinas/genética , Protoporfirinas/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA